VEGFA and colorectal cancer: Moreover, Dll4 expression may influence the sensitivity of endothelial cells to anti-VEGF therapy, with potential implications for the use of bevacizumab and novel anti-Dll4 antibodies in colorectal cancer (Noguera-Troise et al, 2006; Ridgway et al, 2006; Williams et al, 2006; Li et al, 2007).